FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:1395-1397 October 31, 1996 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Spector, S. A.

To the Editor: Spector et al. (June 6 issue)¹ conclude that oral ganciclovir "promises to be a useful drug for prophylaxis against CMV [cytomegalovirus] disease in persons with AIDS [the acquired immunodeficiency syndrome]." The results of their study do not support this statement. The drug's side effects, high cost, and limited efficacy all argue against such a conclusion.

The incidence of granulocytopenia requiring treatment was 15 percentage points higher in the treatment group than in the placebo group. More patients had this complication than were prevented from having CMV, and the granulocytopenia was long-lasting. Granulocyte colony-stimulating factor (G-CSF) was required . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.